肿瘤微环境
免疫系统
癌症研究
癌症
癌症治疗
癌细胞
医学
肿瘤进展
生物
免疫学
内科学
作者
Suling Xu,Yuhan Ma,Xinyu Jiang,Qingqing Wang,Wenxue Ma
出处
期刊:Cancer Letters
[Elsevier]
日期:2024-06-15
卷期号:597: 217072-217072
被引量:2
标识
DOI:10.1016/j.canlet.2024.217072
摘要
CD39 is a pivotal enzyme in cancer, regulating immune response and tumor progression via extracellular ATP and adenosine in the tumor microenvironment (TME). Beyond its established immunoregulatory function, CD39 influences cancer cell angiogenesis and metabolism, opening new frontiers for therapeutic interventions. Current research faces gaps in understanding CD39's full impact across cancer types, with ongoing debates about its potential beyond modulating immune evasion. This review distills CD39's multifaceted roles, examining its dual actions and implications for cancer prognosis and treatment. We analyze the latest therapeutic strategies, highlighting the need for an integrated approach that combines molecular insights with TME dynamics to innovate cancer care. This synthesis underscores CD39's integral role, charting a course for precision oncology that seeks to unravel controversies and harness CD39's therapeutic promise for improved cancer outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI